97 related articles for article (PubMed ID: 32495172)
21. Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma.
Barzon L; Masi G; Boschin IM; Lavezzo E; Pacenti M; Casal Ide E; Toniato A; Toppo S; Palù G; Pelizzo MR
Eur J Endocrinol; 2008 Jul; 159(1):77-80. PubMed ID: 18426810
[TBL] [Abstract][Full Text] [Related]
22. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713
[TBL] [Abstract][Full Text] [Related]
23. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Fugazzola L; Puxeddu E; Avenia N; Romei C; Cirello V; Cavaliere A; Faviana P; Mannavola D; Moretti S; Rossi S; Sculli M; Bottici V; Beck-Peccoz P; Pacini F; Pinchera A; Santeusanio F; Elisei R
Endocr Relat Cancer; 2006 Jun; 13(2):455-64. PubMed ID: 16728573
[TBL] [Abstract][Full Text] [Related]
24. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness.
Trovisco V; Soares P; Preto A; de Castro IV; Lima J; Castro P; Máximo V; Botelho T; Moreira S; Meireles AM; Magalhães J; Abrosimov A; Cameselle-Teijeiro J; Sobrinho-Simões M
Virchows Arch; 2005 Jun; 446(6):589-95. PubMed ID: 15902486
[TBL] [Abstract][Full Text] [Related]
25. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients.
Ito Y; Yoshida H; Maruo R; Morita S; Takano T; Hirokawa M; Yabuta T; Fukushima M; Inoue H; Tomoda C; Kihara M; Uruno T; Higashiyama T; Takamura Y; Miya A; Kobayashi K; Matsuzuka F; Miyauchi A
Endocr J; 2009; 56(1):89-97. PubMed ID: 18840924
[TBL] [Abstract][Full Text] [Related]
26. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas.
Yoon M; Jung SJ; Kim TH; Ha TK; Urm SH; Park JS; Lee SM; Bae SK
Endocr Res; 2016; 41(1):64-9. PubMed ID: 26513490
[TBL] [Abstract][Full Text] [Related]
27. High-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomas.
de Biase D; Cesari V; Visani M; Casadei GP; Cremonini N; Gandolfi G; Sancisi V; Ragazzi M; Pession A; Ciarrocchi A; Tallini G
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1530-8. PubMed ID: 24780046
[TBL] [Abstract][Full Text] [Related]
28. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status.
Abrosimov A; Saenko V; Rogounovitch T; Namba H; Lushnikov E; Mitsutake N; Yamashita S
Int J Cancer; 2007 Jan; 120(1):196-200. PubMed ID: 17044028
[TBL] [Abstract][Full Text] [Related]
29. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.
Basolo F; Torregrossa L; Giannini R; Miccoli M; Lupi C; Sensi E; Berti P; Elisei R; Vitti P; Baggiani A; Miccoli P
J Clin Endocrinol Metab; 2010 Sep; 95(9):4197-205. PubMed ID: 20631031
[TBL] [Abstract][Full Text] [Related]
30. Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.
Rossi M; Buratto M; Bruni S; Filieri C; Tagliati F; Trasforini G; Rossi R; Beccati MD; Degli Uberti EC; Zatelli MC
J Clin Endocrinol Metab; 2012 Jul; 97(7):2354-61. PubMed ID: 22535974
[TBL] [Abstract][Full Text] [Related]
31. Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.
Xu B; Tuttle RM; Sabra MM; Ganly I; Ghossein R
Thyroid; 2017 May; 27(5):632-640. PubMed ID: 28049366
[TBL] [Abstract][Full Text] [Related]
32. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma.
Santarpia L; Sherman SI; Marabotti A; Clayman GL; El-Naggar AK
Hum Pathol; 2009 Jun; 40(6):827-33. PubMed ID: 19200582
[TBL] [Abstract][Full Text] [Related]
33. The Risk of Relapse in Papillary Thyroid Cancer (PTC) in the Context of BRAFV600E Mutation Status and Other Prognostic Factors.
Czarniecka A; Kowal M; Rusinek D; Krajewska J; Jarzab M; Stobiecka E; Chmielik E; Zembala-Nozynska E; Poltorak S; Sacher A; Maciejewski A; Zebracka-Gala J; Lange D; Oczko-Wojciechowska M; Handkiewicz-Junak D; Jarzab B
PLoS One; 2015; 10(7):e0132821. PubMed ID: 26177218
[TBL] [Abstract][Full Text] [Related]
34. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.
Guerra A; Sapio MR; Marotta V; Campanile E; Rossi S; Forno I; Fugazzola L; Budillon A; Moccia T; Fenzi G; Vitale M
J Clin Endocrinol Metab; 2012 Feb; 97(2):517-24. PubMed ID: 22170714
[TBL] [Abstract][Full Text] [Related]
35. The BRAF(V600E) mutation is associated with malignant ultrasonographic features in thyroid nodules.
Lee EJ; Song KH; Kim DL; Jang YM; Hwang TS; Kim SK
Clin Endocrinol (Oxf); 2011 Dec; 75(6):844-50. PubMed ID: 21707687
[TBL] [Abstract][Full Text] [Related]
36. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
37. Molecular alterations in partially-encapsulated or well-circumscribed follicular variant of papillary thyroid carcinoma.
Howitt BE; Jia Y; Sholl LM; Barletta JA
Thyroid; 2013 Oct; 23(10):1256-62. PubMed ID: 23477374
[TBL] [Abstract][Full Text] [Related]
38. High prevalence of B-RAF mutation in papillary carcinoma of the thyroid in north-east Italy.
Girlando S; Cuorvo LV; Bonzanini M; Morelli L; Amadori P; Dalla Palma P; Barbareschi M
Int J Surg Pathol; 2010 Jun; 18(3):173-6. PubMed ID: 20460314
[TBL] [Abstract][Full Text] [Related]
39. BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid Rodolico V; Cabibi D; Pizzolanti G; Richiusa P; Gebbia N; Martorana A; Russo A; Amato MC; Galluzzo A; Giordano C
Cancer; 2007 Sep; 110(6):1218-26. PubMed ID: 17685465
[TBL] [Abstract][Full Text] [Related]
40. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
